Joseiz 100 Tablet contains Lacosamide 100 mg, an antiepileptic agent indicated for the treatment of partial-onset seizures in patients with epilepsy. Lacosamide acts by selectively enhancing slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing without affecting normal neuronal excitability. This mechanism contributes to its efficacy in reducing seizure frequency. Joseiz 100 is typically administered orally and may be used as monotherapy or adjunctive therapy depending on clinical evaluation. The pharmacokinetic profile of Lacosamide demonstrates rapid absorption with peak plasma concentrations occurring within 1 to 4 hours post-dose, and it exhibits linear kinetics with a half-life of approximately 13 hours, allowing for twice-daily dosing. It is primarily eliminated via renal excretion, necessitating dose adjustments in patients with significant renal impairment. Common adverse effects include dizziness, headache, nausea, and diplopia, while serious adverse reactions such as cardiac conduction abnormalities require monitoring, especially in patients with preexisting cardiac conditions. Caution is advised when co-administered with other sodium channel blockers or CNS depressants. Joseiz 100 should be prescribed and monitored by healthcare professionals experienced in managing epilepsy to optimize therapeutic outcomes and minimize risks.